BioPhorum response to the FDA discussion paper on Artificial Intelligence in Drug Manufacturing. It also also presents a global picture of the current state of the biomanufacturing industry on the implementation of AI. It can be used by subject matter experts, business leaders, and key opinion makers to assess their current AI maturity level compared to others and potentially identify future areas of collaboration.
FDA draft guidance
Viewing related articles
Feedback on FDA draft guidance on considerations for the development of CAR-T cell productsÂ
Jun 2022 | Cell & Gene Therapy, Deliverable, Deliverables Report, Feedback to agency, Regulatory Strategy
BioPhorum CGT Regulatory Strategy workstream members provide feedback on the FDA draft guidance on considerations for the development of CAR-T cell products .
Feedback on FDA draft guidance on human gene therapy products incorporating human genome editingÂ
Jun 2022 | Cell & Gene Therapy, Deliverable, Deliverables Report, Feedback to agency, Regulatory Strategy
BioPhorum CGT Regulatory Strategy workstream provided feedback on FDA draft guidance on human gene therapy products incorporating human genome editing .
Feedback on FDA draft guidance for industry studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial
Dec 2021 | Cell & Gene Therapy, Deliverable, Feedback to agency, Regulatory Strategy
BioPhorum members provide feedback on FDA draft guidance for industry studying multiple versions of a cellular or gene therapy product in an early-phase clinical trial.